CLASS II Device recall · Reported 11 Apr 2018 · FDA Enforcement Report

Binding Site Optilite Beta-2-Microglobulin Urine Kit recalled

The Binding Site Group is recalling Binding Site Optilite Beta-2-Microglobulin Urine Kit, distributed in California. The recall was initiated on 9 Mar 2018 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot 407460, UDI 05051700017688
Quantity recalled20 kits distributed to the U.S.

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-1301-2018
FDA event ID
79499
Recalling firm
The Binding Site Group, Birmingham, N/A
Classification
Class II
Status
Terminated
Recall initiated
9 Mar 2018
FDA classified
3 Apr 2018
Reported
11 Apr 2018
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Other Reasons

Timeline

9 Mar 2018Recall initiated by company
3 Apr 2018Classified by FDA+25 days
11 Apr 2018Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

The product is not meeting the antigen excess protection claim of up to 760mg/L, as stated in the Instructions for Use.

Product as listed by the FDA

Binding Site Optilite Beta-2-Microglobulin Urine Kit, Ref LK043.L.OPT.A, IVD. The firm name on the label is The Binding Site Group Ltd., Birmingham, U.K. The Optilite Beta-2-Microglobulin (¿2M) Urine kit is intended for the quantitative in-vitro measurement of beta-2-microglobulin in urine using the Binding Site Optilite analyser to aid in the diagnosis of active rheumatoid arthritis and kidney disease. This test should be used in conjunction with other laboratory and clinical findings.

Where it was distributed

US Distribution was made to CA. There was no foreign/military/government distribution.

California

Questions about this recall

Is Binding Site Optilite Beta-2-Microglobulin Urine Kit recalled?

Yes. The Binding Site Group recalled Binding Site Optilite Beta-2-Microglobulin Urine Kit on 9 Mar 2018. The recall is Class II and its status is Terminated. Recall number Z-1301-2018.

Why was it recalled?

The product is not meeting the antigen excess protection claim of up to 760mg/L, as stated in the Instructions for Use.

Which lots are affected?

Lot 407460, UDI 05051700017688

Where was it sold?

US Distribution was made to CA. There was no foreign/military/government distribution.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from The Binding Site Group

All 29

Other Other Medical Devices recalls

All 13,778